ClearID

Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression 
in Lung Cancer

August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.

Cynvenio Announces ClearID Total Insight, a New Comprehensive LiquidBiopsy Monitoring Program for Breast Cancer

March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.

Cynvenio and Color Partner to Offer Comprehensive Hereditary and Somatic Cancer Testing from Simple Blood Draw

February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.

Cynvenio and Milenia Labs Enter into Exclusive Distribution Agreement for ClearID Breast Cancer Testing in Mexico

January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.

Cynvenio Releases Second-Generation ClearID Breast Cancer Blood Test

January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.

Cynvenio Honors Triple Negative Breast Cancer Day with Clinical Trial Launch and Event at Pink Lotus Breast Center in Los Angeles

March 3, 2016 – Cynvenio Biosystems, Inc. honors Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis. 

ClearID Breast Cancer Genomic Test is Now Reimbursable Under Most Health Insurance Plans

LOS ANGELES, September 16, 2014 – Cynvenio Biosystems, Inc. announces that it will be accepting payment for its ClearID Breast Cancer test under most health insurance plans including Aetna, UnitedHealth Group, Cigna, Assurant, Blue Cross/Blue Shield, Humana, Kaiser Permanente and various Health Maintenance Organizations (HMO), with the exception of Medicaid.

77WABC Radio's Optimal Wellness Hour Features Interview with Andre' de Fusco

September 14, 2014 - Jennifer Smith of 77WABC Radio's Optimal Wellness hour, hosts the second of two interviews discussing the ClearID test.  In this show focused on Breast Cancer awareness, Jennifer speaks with returning guest, Dr. Joe Bosiljevac, and Cynvenio's CEO, Andre' de Fusco.